Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
At RGCC, we offer a whole suite of advanced diagnostic tests to help:
• Produce personalized patient profiles for cancer treatment
• Detect early signs of developing cancer
• Monitor existing cancers
• Follow-up monitoring for possible cancer metastasis
Our tests reveal personalized and granular levels of detail for patients and their specialists on the type of therapeutic drugs and natural substances that can be used to achieve the best outcomes for cancer treatment.
Our tests use our innovative liquid biopsy technique, which uses a blood sample from the patient to carry out analyses.
Our newest Onco-D-clare test takes a proactive step towards early cancer detection and your informed well-being. This test is uniquely tailored for people without symptoms but with a desire for early intervention.
Our Onconomics panels provide deeper insight into the possible treatment options that are likely to work best on your cancer.
The tests check how well various types of anti-cancer drugs and natural substances work to target cancer cells in individual patients. These tests also include genetic detailing on the cancer cells to let you know how gene expressions and physiological expressions manifest in a cancer patient’s body.
Our CTC tests - Oncotrace, Oncotrail RGCC, and Oncocount - are tools for monitoring the progress of cancer treatment for patients. The tests can also provide valuable information that helps in the early detection of cancer recurrence.
Our specialized tests help equip patients and their practitioners with information that can help guide the best treatment choices for each patient. These tests offer advanced diagnostic capabilities that can assess patients’ immune systems, identify chromosomal abnormalities, and prepare for the possibility of cancer metastasis.
CAMBISeq® stands for Cancer Analysis Mutational Burden Instability Sequencing. It provides next-generation sequencing analysis on both DNA and RNA to provide practitioners with crucial insight into one’s cancer.
Our CTC tests - Oncotrace, Oncotrail RGCC, and Oncocount - are tools for monitoring the efficacy and progress of cancer treatment for patients.
Just like the body sheds hair and skin cells, a cancerous tumor sheds cells throughout its lifespan.
These cells are called circulating tumor cells (CTCs), and they can be detected in the bloodstream. Therefore, when a blood sample is analyzed for cancer diagnosis, the test will take a measure of the presence of CTCs.
The CTC tests return a variety of valuable information that helps follow up on how a patient’s body responds to cancer treatment. These tests also help in the early detection of cancer recurrence.
Our Onconomics panels provide deeper insight into the possible treatment options that are likely to work best on your cancer.
The tests check how well various types of anti-cancer drugs and natural substances work to kill cancer cells in individual patients. These tests also include genetic detailing on the cancer cells to let you know how gene expressions and physiological expressions manifest in a cancer patient’s body.
The results of these tests are individualized for each patient since they show how the cancer in your body reacts to each drug or natural substance.
In addition to the CTC tests and the Onconomics panels, we also offer a variety of tests that study the genetic makeup of cancer cells.
Our tests help equip patients and their practitioners with information that can help guide the best treatment choices for each patient. These tests offer advanced diagnostic capabilities that can assess patients’ immune systems, identify chromosomal abnormalities, and prepare for the possibility of cancer metastasis.
Our scientists use cutting-edge technology, equipment, and innovative techniques to develop a range of cancer screening and monitoring tests. Our tests help cancer patients and their healthcare professionals get a comprehensive but personalized view of each patient’s genetics, physiology, and immune profiles.
We believe this level of detail is crucial in developing an individualized care plan for every patient struggling with cancer. We aim to provide a unique insight into every patient’s cancer biology to empower them about what treatment modalities are ideal for bringing them success in their cancer journey!
Reach out to us to start your journey to empowering information for your cancer treatment today by contacting us online.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s Oncocount and Oncotrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s OncoCount and OncoTrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Read more about our therapies on our website: https://rgcc-international.com/rgcc-therapies/
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient’s genes.
Individualized treatment for cancer is the focus behind RGCC’s testing protocols and advanced therapy options. Our slate of tests analyzes the state of a person’s cancer by looking at the cellular and genetic makeup of each patient. Our test results give you information that acts as a blueprint for what treatment protocols are likely to show the most efficacy for your specific biology.
Learn more about RGCC at
https://rgcc-international.com/
Follow us on social media to find out the latest news and updates from our experts.
Facebook: https://www.facebook.com/profile.php?id=61554630098937
Instagram: https://www.instagram.com/rgcc_north_america/
LinkedIn: https://www.linkedin.com/company/r-g-c-c-international-gmbh/
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
